MCID: TNG007
MIFTS: 51

Tongue Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Tongue Carcinoma

Summaries for Tongue Carcinoma

MalaCards based summary : Tongue Carcinoma, also known as tongue cancer, is related to oropharynx cancer and tonsil cancer. An important gene associated with Tongue Carcinoma is BCYRN1 (Brain Cytoplasmic RNA 1), and among its related pathways/superpathways are Innate Immune System and GPCR Pathway. The drugs Nicotine and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and lung, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Tongue Carcinoma

Diseases related to Tongue Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 313)
# Related Disease Score Top Affiliating Genes
1 oropharynx cancer 31.1 TP53 NOTCH1 MMP8 CDH1
2 tonsil cancer 30.9 TP53 NOTCH1 CDH1
3 periodontitis, chronic 30.7 MMP8 MMP1
4 oral cancer 30.7 TP53 PTGS2 MMP9 MMP2 MMP1 CDH1
5 tongue squamous cell carcinoma 30.6 VEGFA TP53 NOTCH1 MTDH MMP9 MMP8
6 papilloma 30.6 VEGFA TP53 PTGS2 CDKN1A CDH1
7 hypopharynx cancer 30.5 TP53 MMP8 CDH1
8 gastric ulcer 30.4 VEGFA TP53 PTGS2
9 endometriosis 30.3 VEGFA TP53 PTGS2 MMP2 MMP1
10 oral squamous cell carcinoma 30.2 VEGFA TP53 MMP9 MMP2 MALAT1 CDH1
11 periodontitis 30.2 VEGFA PTGS2 MMP9 MMP8 MMP2 MMP1
12 pulmonary emphysema 30.1 VEGFA MMP9 MMP8 MMP2 MMP1
13 adenoid cystic carcinoma 29.9 VEGFA TP53 NOTCH1 MMP9 MMP2 CDH1
14 squamous cell carcinoma 29.9 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP2
15 renal cell carcinoma, nonpapillary 29.6 VEGFA TP53 MMP9 MMP2 MALAT1 CDH1
16 leukemia, acute myeloid 29.6 VEGFA TP53 NOTCH1 MMP9 MALAT1 CDKN1A
17 tongue disease 29.5 VEGFA TP53 NOTCH1 MMP9 MMP8 MMP2
18 esophageal cancer 29.4 VEGFA TP53 PTGS2 MMP9 MMP2 MALAT1
19 lung cancer susceptibility 3 29.4 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP2
20 nasopharyngeal carcinoma 29.3 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP2
21 bladder cancer 29.2 VEGFA TP53 PTGS2 MMP9 MMP2 MMP1
22 gastric cancer 29.0 VEGFA TP53 PTGS2 NOTCH1 MTDH MMP9
23 hepatocellular carcinoma 29.0 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP2
24 cervical cancer 28.9 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP2
25 squamous cell carcinoma, head and neck 28.9 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP8
26 colorectal cancer 28.5 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP2
27 vulvar intraepithelial neoplasia 10.7 TP53 CDH1
28 splenic diffuse red pulp small b-cell lymphoma 10.7 TP53 NOTCH1
29 actinic cheilitis 10.7 TP53 CDKN1A
30 invasive bladder transitional cell carcinoma 10.7 TP53 NOTCH1 CDKN1A
31 cystadenocarcinoma 10.7 VEGFA TP53 CDKN1A
32 lip cancer 10.7 TP53 MMP8 CDKN1A
33 pediatric angiosarcoma 10.6 VEGFA TP53
34 dentin caries 10.6 MMP8 MMP20 MMP2
35 sarcomatoid transitional cell carcinoma 10.6 TP53 CDH1
36 skin papilloma 10.6 TP53 PTGS2 CDKN1A
37 esophagus verrucous carcinoma 10.6 TP53 CDH1
38 esophagus adenocarcinoma 10.6 TP53 PTGS2 CDH1
39 keratoacanthoma 10.6 TP53 CDKN1A CDH1
40 colonic benign neoplasm 10.6 TP53 PTGS2 CDH1
41 thyroid tumor 10.6 TP53 MMP2 LGALS3
42 apocrine adenosis of breast 10.6 TP53 BCL2L1
43 tendinopathy 10.6 MMP8 MMP1
44 pancreatic ductal carcinoma 10.6 VEGFA TP53 CDH1
45 adenoma 10.6 TP53 PTGS2 LGALS3 CDH1
46 serous cystadenocarcinoma 10.6 VEGFA TP53 MMP2 CDKN1A
47 fallopian tube carcinoma 10.6 VEGFA TP53 MMP2
48 cervical squamous cell carcinoma 10.6 VEGFA TP53 MMP2 CDH1
49 lymphangioma 10.6 VEGFA TP53 PTGS2 CDH1
50 intestinal benign neoplasm 10.6 VEGFA TP53 PTGS2 CDH1

Graphical network of the top 20 diseases related to Tongue Carcinoma:



Diseases related to Tongue Carcinoma

Symptoms & Phenotypes for Tongue Carcinoma

MGI Mouse Phenotypes related to Tongue Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 BCL2L1 CDH1 CDKN1A DNAJB7 LGALS3 MMP1
2 cardiovascular system MP:0005385 10.13 CDH1 CDKN1A LGALS3 MMP2 MMP9 MTDH
3 immune system MP:0005387 10.13 BCL2L1 CDH1 CDKN1A LGALS3 MMP1 MMP2
4 digestive/alimentary MP:0005381 10.01 CDH1 CDKN1A LGALS3 MMP9 NOTCH1 PTGS2
5 integument MP:0010771 10 BCL2L1 CDH1 CDKN1A DNAJB7 LGALS3 MMP9
6 neoplasm MP:0002006 9.97 BCL2L1 CDH1 CDKN1A LGALS3 MMP1 MMP2
7 renal/urinary system MP:0005367 9.56 CCNB1 CDKN1A LGALS3 MMP9 NOTCH1 PTGS2
8 respiratory system MP:0005388 9.23 CDKN1A LGALS3 MMP2 MMP9 NOTCH1 PTGS2

Drugs & Therapeutics for Tongue Carcinoma

Drugs for Tongue Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Remifentanil Approved Phase 4 132875-61-7 60815
4
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
5
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
6
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
7
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
8
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
9
tannic acid Approved Phase 4 1401-55-4
10
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
11
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
12 Neurotransmitter Agents Phase 4
13 Nicotinic Agonists Phase 4
14 Central Nervous System Stimulants Phase 4
15 Cholinergic Agents Phase 4
16 Anesthetics Phase 4
17 Hypnotics and Sedatives Phase 4
18 Anesthetics, General Phase 4
19 Platelet Aggregation Inhibitors Phase 4
20 Anesthetics, Intravenous Phase 4
21 Anesthetics, Inhalation Phase 4
22
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
23
Promethazine Approved, Investigational Phase 3 60-87-7 4927
24
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
25
Histamine Approved, Investigational Phase 3 51-45-6 774
26
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
27
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
28
Metformin Approved Phase 3 657-24-9 14219 4091
29
Cetuximab Approved Phase 2, Phase 3 205923-56-4 56842117 2333
30 Antiviral Agents Phase 3
31 Interleukin-2 Phase 3
32 Anti-Retroviral Agents Phase 3
33 Anti-HIV Agents Phase 3
34 Vaccines Phase 3
35 Antidepressive Agents Phase 3
36 Histamine Antagonists Phase 3
37 Psychotropic Drugs Phase 3
38
Histamine Phosphate Phase 3 51-74-1 65513
39 Antidepressive Agents, Tricyclic Phase 3
40 Muscarinic Agonists Phase 2, Phase 3
41 Hypoglycemic Agents Phase 3
42 Immunoglobulins, Intravenous Phase 2, Phase 3
43 Antibodies, Monoclonal Phase 2, Phase 3
44
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
45
Indinavir Approved Phase 2 150378-17-9 5362440
46
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
47
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
48
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
49
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
50
Bevacizumab Approved, Investigational Phase 2 216974-75-3

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
2 Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Long-term Survival Rate in Elderly Patients After Cancer Surgery: an Open-label, Randomized Controlled Trial Active, not recruiting NCT02660411 Phase 4 Sevoflurane;Propofol
3 Multicentre Randomised Trial of Inductive and Adjuvant Perilymphatically Injected Proleukin (rlL-2) in The Treatment of Operable Primary Squamous Cell Carcinoma of The Oral Cavity and Oropharynx Unknown status NCT00002702 Phase 3
4 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
5 Phase II Study of the Safety and Efficacy of Allovectin-7® Immunotherapy for the Treatment of Primary, Resectable Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Completed NCT00050388 Phase 3
6 Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract Completed NCT00765440 Phase 3
7 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
8 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
9 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
10 Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
11 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
12 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
13 Role of Neo-adjuvant Chemotherapy in Organ Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue Unknown status NCT02985255 Phase 2 Docetaxel;Cisplatin;5FU
14 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
15 CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment Followed by 6 Weeks of Cetuximab+RT Post Surgery in Locally Advanced Squamous Cell Carcinoma of the Tongue ; A NEW PARADIGM OF TREATMENT Unknown status NCT01760811 Phase 1, Phase 2 Erbitux,merck serono
16 A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
17 A Randomized Phase II Clinical Trial of an Adenovirus-mediated Endostatin Gene (E10A) Combined With Cisplatin and Paclitaxel in Patients With Head and Neck Cancer Unknown status NCT00634595 Phase 2 E10A;Cisplatin;Paclitaxel
18 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
19 Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer Completed NCT02849379 Phase 1, Phase 2
20 High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer Completed NCT03008330 Phase 1, Phase 2
21 Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study Completed NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
22 A Pilot Trial Targeting mTOR as a Novel Mechanism-Based Neoadjuvant Therapy for Head and Neck Cancer Completed NCT01195922 Phase 1, Phase 2 Sirolimus
23 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
24 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
25 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
26 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
27 Do Dietary Supplements of Zinc Reduce Serum Cadmium Levels in Smokers? Completed NCT00376987 Phase 2
28 A Phase IIb Cancer Prevention Trial of Celecoxib, a Selective COX-2 Inhibitor, in Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
29 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
30 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
31 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
32 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
33 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
34 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
35 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
36 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
37 A Phase II Multi-Center Study of Concomitant Cetuximab and Cisplatin With Re-Irradiation Using Intensity-Modulated Radiotherapy in Patients With Recurrent Squamous Cell Carcinoma of the Head-and-Neck Completed NCT00833261 Phase 2 cetuximab;cisplatin;Nab-Paclitaxel
38 Phase II Study Evaluating Radiotherapy-chemotherapy and Cetuximab in Patients With Histologically Proven Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx and With a Poor Prognosis After Complete Surgical Resection Completed NCT00875849 Phase 2 cisplatin
39 Induction Chemotherapy With Cetuximab, Docetaxel, Cisplatin, and Fluorouracil (ETPF)for Squamous Cell Carcinoma of the Oropharynx That is Operable Stage III-IV Completed NCT00665392 Phase 2 cisplatin;docetaxel;fluorouracil;Cetuximab
40 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
41 Phase I/II Study of Induction Chemotherapy With Weekly RAD001, Carboplatin and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
42 A Phase I/II Study of Nab-paclitaxel, Cisplatin and Cetuximab With Concurrent Radiation Therapy for Local-regionally Advanced Head-and-neck Squamous Cell Carcinoma Completed NCT00851877 Phase 1, Phase 2 Cisplatin;Nab-Paclitaxel
43 A Phase II Study of Radiotherapy (IMRT) + Cisplatin + Bevacizumab for Patients With Stage III/IV Head and Neck Cancers Completed NCT00423930 Phase 2 cisplatin
44 A Phase II Trial of Induction Chemotherapy Followed by Cetuximab (Erbitux) With Low Dose vs. Standard Dose IMRT in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx Completed NCT01084083 Phase 2 Paclitaxel;Cisplatin
45 Defining a Personalized Hypoxic Radiation Target Through Correlation of Functional F18-FAZA PET Imaging to Pimonidazole-stained 3D Whole-mounted Histological Specimen Recruiting NCT03181035 Phase 1, Phase 2 Pimonidazole
46 Patient-reported Outcome After Radiotherapy of Oral Cavity and Sinonasal Cancer Using an Intraoral Stent Recruiting NCT04330781 Phase 2
47 A Phase I-II, FIH Study of A166 in Locally Advanced/Metastatic Solid Tumors Expressing Human Epidermal Growth Factor Receptor 2 (HER2) or Are HER2 Amplified That Did Not Respond or Stopped Responding to Approved Therapies Recruiting NCT03602079 Phase 1, Phase 2 A166
48 Phase II Study: Induction Chemotherapy Followed by Transoral Robotic Surgery and Neck Dissection for Definitive Management of Oropharyngeal Squamous Cell Carcinoma. (NECTORS Trial) Recruiting NCT04277858 Phase 2 Docetaxel
49 Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study. Active, not recruiting NCT02748707 Phase 2 Arm1;Arm 2;Arm 3
50 A Phase II Study of Tongue Conservation Surgery for Advanced Oral Tongue Cancer: Induction Chemotherapy, Followed by Tongue Conservation Surgery and Postoperative Chemoradoitherapy Terminated NCT03161548 Phase 2 Induction chemotherapy

Search NIH Clinical Center for Tongue Carcinoma

Cochrane evidence based reviews: tongue neoplasms

Genetic Tests for Tongue Carcinoma

Anatomical Context for Tongue Carcinoma

MalaCards organs/tissues related to Tongue Carcinoma:

40
Tongue, Lymph Node, Lung, Tonsil, Endothelial, Brain, Bone

Publications for Tongue Carcinoma

Articles related to Tongue Carcinoma:

(show top 50) (show all 2080)
# Title Authors PMID Year
1
Emodin induces apoptosis of human tongue squamous cancer SCC-4 cells through reactive oxygen species and mitochondria-dependent pathways. 61 54
19331169 2009
2
Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. 61 54
18253113 2008
3
Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer. 61 54
17611661 2007
4
NF-kappaB signaling pathway is involved in growth inhibition, G2/M arrest and apoptosis induced by Trichostatin A in human tongue carcinoma cells. 61 54
17005413 2006
5
Carcinoma of tongue and the buccal mucosa represent different biological subentities of the oral carcinoma. 54 61
16767431 2006
6
Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. 61 54
16331606 2006
7
[Effects of arsenic trioxideon the cell apoptosis and hTERT mRNA of human tongue cancer cells]. 54 61
16285558 2005
8
The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. 54 61
15289890 2004
9
Molecular analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence of 1,25(OH)2 vitamin D3 and its analogs. 54 61
14977084 2004
10
Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. 54 61
14730689 2004
11
MMP-9 activation by tumor trypsin-2 enhances in vivo invasion of human tongue carcinoma cells. 61 54
12454097 2002
12
Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. 54 61
11900224 2002
13
A comparative study of the clinicopathological significance of E-cadherin and catenins (alpha, beta, gamma) expression in the surgical management of oral tongue carcinoma. 54 61
11206273 2001
14
Inostamycin, an inhibitor of cytidine 5'-diphosphate 1,2-diacyl-sn-glycerol (CDP-DG): inositol transferase, suppresses invasion ability by reducing productions of matrix metalloproteinase-2 and -9 and cell motility in HSC-4 tongue carcinoma cell line. 54 61
11315101 2000
15
p53, p21, Rb, and MDM2 proteins in tongue carcinoma from patients < 35 versus > 75 years. 61 54
10645402 1999
16
Tenascin: growth and adhesion modulation--extracellular matrix degrading function: an in vitro study. 61 54
8736172 1996
17
Expression of the cell-cell adhesion molecule E-cadherin in tongue carcinoma cell lines. 61 54
7829949 1994
18
Circulating prolactin and tumoral prolactin receptors in men with tongue cancer: a preliminary study. 61 54
8181582 1994
19
Sonographicdetectionof a metastatic lingual lymph node in a patient with tongue cancer. 61
32243597 2020
20
Histological characteristics of early-stage oral tongue cancer in young versus older patients: A multicenter matched-pair analysis. 61
31994277 2020
21
Tumor histologic grade as a risk factor for neck recurrence in patients with T1-2N0 early tongue cancer. 61
32330684 2020
22
Functional Outcomes Regarding Facial Artery Musculomucosal Flap for Reconstruction of Partial Glossectomy Defects. 61
32187069 2020
23
[Whole-course, individualized, and standardized sequential nutrition therapy for radical resection of tongue cancer: a case report]. 61
32573147 2020
24
Impairments in Food Oral Processing in Patients Treated for Tongue Cancer. 61
31598793 2020
25
Survival prediction for oral tongue cancer patients via probabilistic genetic algorithm optimized neural network models. 61
32520585 2020
26
Transcriptome analysis of tongue cancer based on high‑throughput sequencing. 61
32236620 2020
27
The Role of Age and Merkel Cell Polyomavirus in Oral Cavity Cancers. 61
32571145 2020
28
Comparison of Intraoperative Sonography and Histopathologic Evaluation of Tumor Thickness and Depth of Invasion in Oral Tongue Cancer: A Pilot Study. 61
32554422 2020
29
Extent of neck dissection for patients with clinical N1 oral cancer. 61
32140953 2020
30
Oral cavity cancer incidence rates in Osaka, Japan between 2000 and 2014. 61
32272382 2020
31
TCRP1 induces tamoxifen resistance by promoting the activation of SGK1 in MCF‑7 cells. 61
32323833 2020
32
Crosslinked nanogel-based porous hydrogel as a functional scaffold for tongue muscle regeneration. 61
32208921 2020
33
Level IV neck dissection as an elective treatment for oral tongue carcinoma-a systematic review and meta-analysis. 61
32540318 2020
34
Squamous Cell Carcinoma of the Oral Tongue in Young Patients: Outcomes and Implications for Treatment. 61
32523275 2020
35
[Influence of mandibulotomy approaches on oral function following radical resection of tongue carcinoma]. 61
32573135 2020
36
An examination of the cutoff value of the depth of invasion for prophylactic neck dissection in stage I/II tongue cancer. 61
32022616 2020
37
SMARCD1 is a transcriptional target of specific non-hotspot mutant p53 forms. 61
31637714 2020
38
Polish Propolis-Chemical Composition and Biological Effects in Tongue Cancer Cells and Macrophages. 61
32455950 2020
39
Adjuvant Postoperative CD40 Agonist and PD-1 Antagonist Combination Therapy in Syngeneic Tongue Cancer Mouse Model. 61
32366416 2020
40
Grade as prognostic variable in early tongue cancer patients: Are we getting off the track? 61
32471802 2020
41
Patient-Reported Quality of Life After Resection With Primary Closure for Oral Tongue Carcinoma. 61
32379355 2020
42
Granulocyte colony-stimulating factor-producing squamous cell carcinoma of the tongue exhibiting characteristic fluorine-18 deoxyglucose accumulation on positron emission tomography-computed tomography: A case report. 61
32432145 2020
43
Oral squamous cell carcinoma of the tongue dorsum with multiple cancer-associated mutations in the TP53 gene. 61
32451170 2020
44
Persistent and Chronic Postoperative Opioid Use in a Cohort of Patients with Oral Tongue Squamous Cell Carcinoma. 61
31609416 2020
45
Anatomically-based transoral surgical approach to early-stage oral tongue squamous cell carcinoma. 61
32003091 2020
46
Modified in-continuity resection is advantageous for prognosis and as a new surgical strategy for management of oral tongue cancer. 61
32102766 2020
47
Comparison of Clinical Results and Quality of Life in Tongue Cancer Patients Undergoing Submental Island Flap and Radial Forearm Free Flap Reconstruction. 61
32504562 2020
48
Oncological outcomes in patients undergoing major glossectomy for advanced carcinoma of the oral tongue. 61
32436723 2020
49
Keratin 36, a specific marker of tongue filiform papillae, is downregulated in squamous cell carcinoma of the mobile tongue. 61
32257198 2020
50
Detection and Implications of Occult Contralateral Nodal Spread in Human Papillomavirus-Associated Base of Tongue Cancer. 61
32239194 2020

Variations for Tongue Carcinoma

Expression for Tongue Carcinoma

Search GEO for disease gene expression data for Tongue Carcinoma.

Pathways for Tongue Carcinoma

Pathways related to Tongue Carcinoma according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 VEGFA TP53 PTGS2 MMP9 MMP8 MMP2
2
Show member pathways
13.55 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP8
3
Show member pathways
13.32 VEGFA TP53 PTGS2 MMP9 MMP2 MMP1
4
Show member pathways
12.97 VEGFA TP53 PTGS2 NOTCH1 CDKN1A BCL2L1
5
Show member pathways
12.92 VEGFA TP53 PTGS2 CDKN1A CCNB1 BCL2L1
6
Show member pathways
12.85 VEGFA TP53 MMP9 CDKN1A CDH1 BCL2L1
7
Show member pathways
12.74 TP53 NOTCH1 CDKN1A CDH1 BCL2L1
8
Show member pathways
12.71 MMP9 MMP8 MMP20 MMP2 MMP1 CDH1
9 12.68 VEGFA TP53 PTGS2 NOTCH1 MMP9 MMP2
10
Show member pathways
12.61 TP53 NOTCH1 MMP9 MMP2 CDKN1A CDH1
11 12.46 VEGFA TP53 PTGS2 NOTCH1 MMP9 CDKN1A
12
Show member pathways
12.36 TP53 CDKN1A CCNB1 BCL2L1
13 12.35 TP53 CDKN1A CDH1 CCNB1
14 12.26 VEGFA TP53 MMP9 MMP2 CDKN1A
15 12.25 TP53 MMP9 CDKN1A BCL2L1
16 12.14 VEGFA TP53 MMP1 CDH1
17 12.08 VEGFA TP53 MMP9 MMP2
18 12.05 TP53 MMP2 CDKN1A CCNB1
19 12 MTDH MMP9 MMP2 CDH1
20 11.97 TP53 PTGS2 MMP9 LGALS3
21 11.84 TP53 PTGS2 CDKN1A BCL2L1
22
Show member pathways
11.83 MMP9 MMP8 MMP20 MMP2 MMP1
23 11.82 TP53 CDKN1A CCNB1
24
Show member pathways
11.82 TP53 CDKN1A CCNB1
25 11.82 PTGS2 NOTCH1 MMP9 MMP2
26 11.79 TP53 MMP1 CDKN1A
27 11.77 MMP9 MMP2 CDH1
28 11.77 TP53 MTDH MMP9 CCNB1
29 11.76 PTGS2 CDKN1A CCNB1
30 11.72 TP53 CDKN1A BCL2L1
31 11.7 VEGFA TP53 MMP2 CDKN1A
32 11.67 MMP9 MMP2 LGALS3
33 11.63 MMP9 MMP2 MMP1
34 11.61 VEGFA TP53 PTGS2 MMP9 MMP2 MMP1
35 11.59 VEGFA PTGS2 MMP9 CDKN1A
36
Show member pathways
11.57 VEGFA PTGS2 MMP9 MMP2 MMP1
37 11.56 VEGFA TP53 MMP9 MMP2 MMP1 CDKN1A
38 11.51 VEGFA PTGS2 CDKN1A
39 11.51 VEGFA TP53 PTGS2 MMP1 CDKN1A BCL2L1
40 11.49 TP53 MMP1 CDKN1A
41 11.49 TP53 MMP2 CDKN1A BCL2L1
42 11.49 VEGFA TP53 PTGS2 MMP9 MMP2 MMP1
43 11.4 MMP9 MMP1 LGALS3
44 11.33 VEGFA TP53 PTGS2 BCL2L1
45 11.32 MMP9 MMP2 MMP1
46 11.28 TP53 CDKN1A CCNB1
47 10.77 TP53 CDKN1A BCL2L1
48
Show member pathways
10.58 TP53 CDKN1A

GO Terms for Tongue Carcinoma

Cellular components related to Tongue Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 VEGFA NOTCH1 MMP9 MMP8 MMP20 MMP2
2 extracellular matrix GO:0031012 9.1 VEGFA MMP9 MMP8 MMP20 MMP2 MMP1

Biological processes related to Tongue Carcinoma according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10 VEGFA TP53 PTGS2 MTDH MMP9 CDKN1A
2 response to drug GO:0042493 9.96 TP53 PTGS2 CDKN1A CDH1 CCNB1
3 angiogenesis GO:0001525 9.92 VEGFA PTGS2 NOTCH1 MMP2
4 negative regulation of gene expression GO:0010629 9.91 VEGFA TP53 NOTCH1 MMP8 CDKN1A CCNB1
5 in utero embryonic development GO:0001701 9.88 VEGFA TP53 NOTCH1 CCNB1 BCL2L1
6 response to organic substance GO:0010033 9.8 PTGS2 CDKN1A CDH1
7 extracellular matrix organization GO:0030198 9.8 MMP9 MMP8 MMP20 MMP2 MMP1 CDH1
8 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.77 TP53 CDKN1A CCNB1
9 cellular response to hypoxia GO:0071456 9.77 VEGFA TP53 PTGS2 MALAT1 CCNB1
10 positive regulation of protein complex assembly GO:0031334 9.76 VEGFA MMP1 LGALS3
11 embryo implantation GO:0007566 9.74 PTGS2 MMP9 MMP2
12 cellular response to gamma radiation GO:0071480 9.71 TP53 CDKN1A BCL2L1
13 endodermal cell differentiation GO:0035987 9.7 MMP9 MMP8 MMP2
14 tissue regeneration GO:0042246 9.67 NOTCH1 CDKN1A CCNB1
15 cardiac septum morphogenesis GO:0060411 9.64 TP53 NOTCH1
16 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.63 TP53 CDKN1A
17 replicative senescence GO:0090399 9.62 TP53 CDKN1A
18 tube formation GO:0035148 9.61 VEGFA NOTCH1
19 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.61 VEGFA NOTCH1
20 coronary artery morphogenesis GO:0060982 9.6 VEGFA NOTCH1
21 signal transduction by p53 class mediator GO:0072331 9.58 TP53 CDKN1A
22 regulation of neuroinflammatory response GO:0150077 9.58 PTGS2 MMP9 MMP8
23 cardiac vascular smooth muscle cell development GO:0060948 9.55 VEGFA NOTCH1
24 extracellular matrix disassembly GO:0022617 9.55 MMP9 MMP8 MMP20 MMP2 MMP1
25 coronary vein morphogenesis GO:0003169 9.51 VEGFA NOTCH1
26 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.43 VEGFA TP53 NOTCH1
27 collagen catabolic process GO:0030574 9.35 MMP9 MMP8 MMP20 MMP2 MMP1
28 cytokine-mediated signaling pathway GO:0019221 9.23 VEGFA TP53 PTGS2 MMP9 MMP2 MMP1

Molecular functions related to Tongue Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.8 TP53 MMP9 MMP8 MMP20 MMP2 MMP1
2 peptidase activity GO:0008233 9.77 MMP9 MMP8 MMP20 MMP2 MMP1
3 serine-type endopeptidase activity GO:0004252 9.56 MMP9 MMP8 MMP2 MMP1
4 endopeptidase activity GO:0004175 9.46 MMP9 MMP8 MMP2 MMP1
5 metallopeptidase activity GO:0008237 9.35 MMP9 MMP8 MMP20 MMP2 MMP1
6 metalloendopeptidase activity GO:0004222 9.02 MMP9 MMP8 MMP20 MMP2 MMP1

Sources for Tongue Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....